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Abstract 
Objective: Making best use of existing skills to increase service capacity is a global challenge. 
The aim was to systematically review physiotherapy and podiatrist prescribing and medicines 
management activity, including evidence of impact on patient care, levels of knowledge and 
attitudes towards extended medicines role. 
Methods: A search of MEDLINE, CINAHL, and Cochrane databases, using terms to identify 
prescribing and medicines management across a range of roles, was conducted from January 
1985 to May 2016 for physiotherapy, and January 1968 to May 2016 for podiatry. Hand 
searching of citations and databases from professional organisations was undertaken. Data 
were extracted and analysed descriptively, and quality appraised by 2 reviewers using the 
mixed methods appraisal tool. 
Results: 1316 papers were identified, and 21 included in the review. No studies were identified 
that reported prescribing and no studies specific to podiatry met the inclusion criteria. 
Physiotherapists were highly involved in administering medicines, providing medicines 
advice, and recommending new medicines. Patient satisfaction, cost and outcomes were 
equivalent when comparing physiotherapist-led injection therapy to traditional care.  
Pharmacology knowledge was variable and unmet training needs identified.  
Conclusion: Medicines management practices were identified in physiotherapy and positive 
outcomes of extended scope physiotherapy. There was a lack of evidence regarding podiatric 
practice. Review of educational preparation for medicines management is recommended along 
with  evaluation of medicines management practice. 
Keywords: Policy development; Physiotherapy; Podiatry; Medicines management; 
Prescribing; Systematic review; Allied Health Professions  
 
 
  
INTRODUCTION  
Given increasing demand on health services, there is a need for strategies to build sustainable 
health systems with improved reach and efficiency (1). A report by the World Health 
Organisation (2) focuses on the important role of research in advancing progress towards 
universal health coverage. Understanding how to make the best use of existing skills and 
resources has been identified as a global challenge (2). One strategy to improve coverage is to 
extend the range of professionals who can prescribe medicines to include nurses, pharmacists 
and allied health professionals (AHPs). Prescribing by nurses and pharmacists offers care 
comparable to that provided by doctors and can improve patient satisfaction, access and 
adherence to medicines (3,4). AHPs, such as physiotherapists and podiatrists, often work 
independently and can be the first point of contact for patients, making them ideally placed to 
undertake advanced practice roles in assessment, diagnostics and administration of medicines 
(5). If these professionals can prescribe medicine, it may prevent an appointment with a doctor 
and improve timeliness and access to treatment (6).  
Physiotherapy is a recognised profession in over 110 countries and more than a million 
practitioners work in healthcare and/or as independent practitioners (7). Concerned chiefly with 
human function and movement (8), physiotherapy identifies and maximizes quality of life and 
movement potential within the five spheres of promotion, prevention, treatment/intervention 
and rehabilitation (7). There is evidence that advanced practice physiotherapists provide care 
that is equal to doctors in relation to diagnostic accuracy, patient satisfaction, treatment 
effectiveness and costs (9). Recognition of podiatry as a profession varies internationally. 
Podiatrists in the UK deliver a variety of physical, pharmaceutical and related interventions 
aimed at improving foot health and mobility (10) and work within general clinics, paediatrics, 
biomechanics, and high risk patient management. Some also specialise in foot surgery, 
achieving consultant podiatric surgeon status (11). 
Physiotherapists and podiatrists in the UK can administer medicine under the legal framework 
of Patient Group Directions (PGDs) (see Table 1 for glossary of terms). There are an estimated 
3,000 physiotherapists trained in injection therapy in the UK (6) Podiatrists have had access to 
local anaesthesia since the 1970s and the ability to administer and supply a limited number of 
prescription only medicines via exemptions for 10 years (Table 1). Following the introduction 
of a form of dependent prescribing (Supplementary prescribing) in 2005 (6) legislative change 
in 2013 has entitled physiotherapists and podiatrists to prescribe medicine independently of a 
doctor (Table 1). It is anticipated that independent prescribing will improve patient access to 
medicines, service efficiency and quality of care (12) and is aligned with current health policy 
encouraging one-stop-shop services that meet demand at the point of contact (13,14). Other 
countries have seen similar role extension within physiotherapy and podiatry, however 
legislation to prescribe appears to be limited to military physiotherapists in the USA and 
podiatrists in some Canadian states (15). Physiotherapists have authorisation to provide advice 
about and/or to administer or supply medicines in some states in Australia, New Zealand and 
Canada, and podiatrists have similar authority in Australia and some European countries.  
 
It is important to assess current practice in order to scope the potential contribution of AHPs to 
medicines delivery, however the extent of physiotherapy and podiatry involvement in 
medicines management is largely unknown. Systematic reviews on AHP roles have identified 
that most studies are of low quality and few report on patient outcome measures (5, 24-25). 
International literature focusing on medicines delivery is limited and there has been no 
comprehensive review of this evidence to date. This review will therefore examine the current 
literature relating to prescribing and other medicines management activity by physiotherapists 
and podiatrists.  
 
Aim 
To systematically review current evidence regarding physiotherapy and podiatrist prescribing 
and medicines management activity, including evidence of impact on patient care, levels of 
knowledge and attitudes towards extended medicines role.  
METHODS 
This review was conducted following the guidelines offered by the Preferred Reporting Items 
of Systematic Reviews and Meta-Analysis (PRISMA) framework (26). The study aims were 
structured using the elements of PICO (Population, intervention, comparator and outcome). 
See Table 2.    
Search Strategy 
The search strategy was applied across international electronic databases MEDLINE, CINAHL 
(via EBSCO) & Cochrane, supplemented with hand searching of relevant citations. Further 
searches were conducted using databases from professional organisations (n=11) and trial 
registers (n=4) (Appendix 1). Searches were conducted from the first recorded modern day 
activity on medicines management in the literature, as determined by a prior scoping search: 
January 1998 to May 2016 (physiotherapy), and January 1968 to May 2016 for podiatry. 
Search terms represented medicines management and prescribing activities across a range of 
professional roles and across a range of care settings (Appendix 2). Each database was searched 
using the Index Terms (i.e. MeSH/index terms) unique to each database and a combination of 
Boolean (AND/OR) keywords in the title or abstract. Search strategies were developed by JE 
and checked by FM. No limits were placed on the searches at this stage other than inclusion of 
papers published in English. Search results were stored and managed using Endnote (v7.2). 
The total number of papers identified was 1316 and of these 130 were duplications across 
databases. At this stage 1186 articles were subject to screening. 
Study Selection, Screening and Data Extraction 
Titles and abstracts were screened independently by two authors using the criteria detailed in 
Table 2. No limits were placed on methodology, clinical speciality, health care setting, or 
geographical area in order to be inclusive of all internationally relevant literature regardless of 
differences in healthcare setting. Disagreement was resolved by reviewing and discussing the 
full text version with the author team. A data extraction form (Table 3) was created to capture 
details about the study design, data collection methods, intervention, participant characteristics, 
outcome measures, study findings and study limitations.  Data was also captured which would 
inform our review questions. This included information on: 
 service settings/ characteristics; 
 medicines management activities; 
 level of knowledge or attitudes towards prescribing roles; 
 issues that may impact on medicines management role; 
 any evidence for the effectiveness of these roles. 
Data extraction was undertaken by JE, FM, KS and NC content was discussed in regular author 
team meetings.  
Data Quality 
Quality was evaluated using the Mixed Methods Appraisal Tool (MMAT) (27-28). The MMAT 
includes 3 methodological domains; mixed methods, qualitative and quantitative (the latter 
subdivided as randomised controlled, non-randomised and descriptive) (29). Domains are 
scored on 4 criteria, assigned 25% each, thereby affording an individual score out of 100. The 
inter-rater reliability of the MMAT is 0.94 (28). Two authors (JE & FM) appraised each study. 
Disagreement was resolved with a discussion in the author team meeting.  For the purposes of 
this review, a score of less than 50 was considered low quality and excluded. Scores 50 and 75 
were considered medium quality and 100 considered high quality. The MMAT scores for 
individual studies are presented in Table 3.  
Analysis 
Data was analysed thematically; focusing on data which would answer our key research 
questions. Experimental trials included in this review used different outcome measures and, 
due to heterogeneity, we were unable to conduct a meta-analysis.  
REVIEW FINDINGS 
Of the 32 eligible empirical studies, 21 scored 50 or over on the MMAT and were included in 
the review. Papers reported on 17 studies, including: randomised controlled trials (n=3), cohort 
studies (n=3), case series (n=1), questionnaire surveys (n=8) and qualitative (n=2).  Papers 
originated from Australia (n=7), New Zealand (n=1), Nigeria (n=2), South Africa (n=1), UK 
(n=9) and USA (n=1). Details of the final included papers are presented in the Preferred 
Reporting Items for Systematic reviews and Meta-analysis (PRISMA) flowchart (Appendix 3) 
and Table 3. 
No studies were identified that specifically evaluated prescribing by physiotherapists or 
podiatrists and no studies relating specifically to podiatry met the inclusion criteria. 
Four main themes were identified in the data relating to physiotherapy. These were: 
1. Extent of involvement in medicines advice or administration.  
2. Knowledge levels and training needs relating to role in medicines management or 
advice. 
3. Attitudes towards physiotherapist prescribing or extended medicines role.  
4. Care outcomes and costs.  
 
1. Extent of involvement in medicine advice or administration  
Nine articles (30-38) provided evidence that physiotherapists are involved in: a) administering 
medicines to clients or b) advising about or recommending medicines. With the exception of a 
case series study (30), all were questionnaire surveys.  
a) Administration of medicines 
Research commissioned in Australia (32-35) followed concerns that physiotherapists were 
practicing outside New South Wales medicines legislation that allows the administration of 
Prescription Only Medicines (POM) once medicines have been obtained by the patient. Of the 
472 physiotherapists surveyed (32), 27% administered POMs, of which 6% were acting outside 
the legal framework by independently deciding on dosage without medical instruction. The 
study also found that Over the Counter (OTC) medicines, which appropriately trained 
physiotherapists in Australia are permitted to administer, were administered on a weekly (32%) 
or daily (17%) basis. Private practitioners were more engaged in administering OTC medicine 
than publicly funded practitioners (34). A further study (37) surveyed Australian 
physiotherapists with respect to use of non-steroidal anti-inflammatories (NSAIDs) available 
OTC: topical NSAIDs were regularly applied by 20%, of the sample (n=285) against 
professional practice guidance. Similarly, in South Africa (where administration, storage and 
prescribing of medicines by physiotherapists is not supported by current legislation), 64% of 
461 physiotherapists surveyed (38) reported administering medicines and 26% stocked 
medicines. 
 
In North America, physiotherapist roles were found to affect their involvement in medicines 
administration (36). In this survey, physiotherapists providing healthcare at the first point of 
entry into primary care (primary contact roles) were more frequently involved in administration 
of OTC medications and ordering imaging studies than those in non-primary contact roles. 
Three groups were recruited: civilian primary contact physiotherapists (n=37), military primary 
contact physiotherapists (n=82), and non-primary contact civilian physiotherapists (n=103). 
OTC medicines were administered by 61% of military and 38% of civilian physiotherapists, 
mainly for MSK conditions, compared to 6.2% of non-primary contact physiotherapists. 
Establishing a physical therapy diagnosis and prescribing or administering OTC were 
considered to be important professional tasks in these roles, as was maintaining effective 
communication with physicians and other healthcare providers. The legislative framework for 
non-military physiotherapist involvement in administering medicine in this study was unclear. 
Only one study (30) reported on physiotherapists’ role in medicines administration in the UK. 
This study focused on intra-articular injections for knee osteoarthritis in an outpatient clinic, 
finding similar outcomes to physician-led services.  
b) Advising and recommending medicines 
Direct evidence of physiotherapist involvement in advising patients about medication was 
reported in surveys conducted in Australia (34-35,37) and New Zealand (31). In Australia, 
while most physiotherapists questioned new clients about POM (61.5%) and OTC (74%) 
medicine use, fewer (53%) kept a record of POMs, and 24.4% considered this information 
when planning a treatment regime (35).  The majority advised clients about prescription (86%) 
and OTC (82%) medicine (33,34). This included advising clients to consult a doctor, advising 
how and when to take medicines, where to obtain them and when to cease them (33,34), as 
well as precautions, contraindications and side-effects (37). Reasons for providing advice 
included: having been asked by clients; detecting incorrect use or ineffective medicine regime; 
and advice given by the doctor being perceived as inadequate. Those who did not provide 
advice were concerned about inadequate training and a lack of legal entitlement and 
responsibility for this role (33,34). 
In New Zealand, a survey of musculoskeletal physiotherapists (n=278) found that the majority 
(81%) recommend oral NSAIDs or paracetamol to clients, often advising purchase of 
paracetamol over the counter (31). Information on risks and side effects was routinely provided 
by 83%.  
2. Knowledge levels and training needs relating to role in medicines management or 
advice 
A need for more comprehensive training in pharmacology is highlighted in several surveys 
(31-32,35,37-40). Focusing on topical analgesics, anti-inflammatory agents, and antibiotics, a 
Nigerian study (39) concluded that awareness of common drug doses was poor and there was 
a need for updated knowledge amongst physiotherapists. Similarly, in Australia (35) and New 
Zealand (31) many respondents indicated large gaps in self-reported knowledge, with 
insufficient training cited as a considerable issue (37). At the time of these reports, Australia 
lacked competency standards or a set standard for curriculum content for pharmaceutical 
education for physiotherapists. A similar pattern is reported for South Africa where variable 
access to initial and ongoing training in pharmacology was reported despite the fact that 
pharmacological training guidelines for physiotherapists have existed since 1994 (38). 
3. Attitudes towards physiotherapist prescribing or extended medicines role  
Overall, physiotherapists in South Africa (38), Nigeria (39) and the UK (41), support an 
increased role in medicines management and prescribing. Anticipated benefits of this advanced 
role include: increased quality of care; improved service efficiency; use of skills; and enhanced 
professional status. Barriers cited include: the need for more comprehensive pharmacology 
training; issues with liability and insurance cover; and resistance to changes to traditional roles 
(38,41-42). Physiotherapists undertaking extended roles in medicines management are reported 
to experience an initial lack of confidence and an increased awareness of risks and 
contraindications (41). In Australia, rural, sports and first contact physiotherapists have been 
in favour of extending their role for prescribing of NSAIDs, if support is provided from 
pharmacists (43). In contrast, evidence suggests that hospital-based physiotherapists are less 
supportive of increasing their involvement in medicines or prescribing (37,43). Mixed views 
with regards to providing advice, along with concerns about legality, access to medical records 
and patient safety have been reported, despite physiotherapists routinely being asked by clients 
for medicines advice (32-33, 35,43). 
Healthcare professionals in the UK (42) and Australia (44), are reported to be confident in the 
ability of physiotherapists to undertake advanced tasks in diagnosing and treating 
musculoskeletal conditions, although not all are supportive of a prescribing role (42). Patients 
were reported to be satisfied with the care provided by an advance scope physiotherapist, 
although not all patients were aware that they were seeing a physiotherapist rather than a doctor 
(45). 
4. Care and cost outcomes 
Outcomes of physiotherapist-led assessment and management, as compared to routine care 
provided by doctors or nurses was the subject of 6 papers: three randomised controlled trials 
(RCTs) (45-47), two cohort studies (44,48), and a retrospective case note review (49). Three 
studies included economic data (45-46, 50). 
In a RCT by Daker-White et.al. (46), new referrals to two UK orthopaedic outpatient 
departments were randomly allocated to assessment and management by extended scope 
physiotherapists (ESPs) or to trainee surgeons. ESPs received one-to-one training by a 
consultant to instigate (but not prescribe) the same management options as doctors, including 
intra-articular injections and analgesics. No significant differences were found between groups 
at 6 months in any outcomes apart from the ‘perceived treatment quality’ subscale of patient 
satisfaction which favoured the ESP arm. In-hospital costs were reduced in the ESP arm who 
requested fewer x-rays and surgical referrals. 
Outcomes of care provided by physiotherapists to patients with soft tissue injury in UK 
emergency departments were compared to usual care provided by doctors and emergency nurse 
practitioners (ENP) in four papers (45,47,48,50). In these studies, physiotherapists were able 
to supply or administer analgesia via PGD. The first was a block randomised, non-inferiority 
trial in an accident and emergency department (45). Results showed higher satisfaction and 
quality of life at 3 months in the physiotherapy arm, but no differences in outcomes at 6 months. 
A similar and more recent block RCT in an emergency department reported equivalence in 
functional outcomes and health related quality of life at 8 weeks and no difference in recovery 
rates between the 3 professional groups (47). A single centre prospective cohort study (48) 
reported equivalent functional outcome scores at 1 week follow-up across the three staff 
groups. Patient satisfaction was higher in the ESP group for advice, explanation of assessment 
and time to ask questions, however ESPs were found to spend more time with patients than 
ENPs or doctors (25 minutes, compared to 15 and 20 respectively) (48).  In an Australian ED 
department, a prospective cohort study was used to assess the impact of an Advanced Scope of 
Practice Physiotherapist (ASoP-PP) service on triage targets (44). Requests for imaging and 
prescriptions were made via doctors as there was no legislation to allow the ASoP-PP to 
independently provide medicines management in Australia, however these tasks made up 50-
70% of the volume of provision per patient.  The service did not significantly impact on 
compliance rates with triage targets but did significantly reduce length of stay and length of 
wait on shifts where the ASoP-PP was present. While these latter studies support the case for 
ESP role in minor injury care, the long term impact was not assessed.  
 In all settings studied, physiotherapists were recorded as providing more general advice and 
reassurance to patients than doctors or nurses (46,49), but less specific advice or analgesia (45-
47,49,50). 
 
Economic data collected by Richardson et.al.(45) on use of health and social services and 
personal costs at treatment and follow-up showed no significant differences in service related 
or health and social care costs. However, patterns of service use were different, for example, 
fewer prescriptions were issued in the physiotherapy arm but referrals to other services were 
higher.  A cost-minimisation analysis from the McLellan trial (50) based on data collected 
during 8 weeks following injury,  indicated that ESPs are at best equivalent, if not more 
expensive than routine care. While indirect costs were equivalent or more expensive, direct 
costs were equivalent or cheaper for the ESP group, mainly due to preference for supplying 
supportive equipment (e.g. leg crutches, braces) than administering medicine.  
 
Data Quality 
Overall study quality was moderate, with only one study identified as high quality (30), and a 
lack of podiatry related evidence. Generalisability of the descriptive studies was limited in 
many cases by low response rates (under 40% response rate in 4 studies: 32, 36-38). The range 
and variability of outcome measures used in the RCTs, differing lengths of follow-up and under 
powering in some studies make it difficult to generalise the findings from this aspect of the 
review (46). 
 
 
DISCUSSION 
This is the first comprehensive systematic review of physiotherapist and podiatrist prescribing 
and medicines management activity and related outcomes. The review is timely and of 
international relevance given the potential to improve health services through making better 
use of the skills of AHPs (51). 
The review identified a lack of research on podiatrist involvement in medicines management. 
In contrast, a range of predominantly descriptive studies report on physiotherapy involvement 
in medicines management, with some medium and high quality intervention studies. In line 
with findings from a systematic review of non-medical prescribing (4), there is some evidence 
from RCTs that care provided by ESPs with training in MMA is equivalent to that of doctors 
or nurses in emergency and orthopaedic departments. However, long-term outcomes have not 
been studied and economic analysis indicates that ESP care may be more expensive in some 
respects.  While there is evidence of increased patient satisfaction for ESP care, this may be 
attributable to longer consultation times and more research is needed to further investigate these 
differences. 
There is a high level of involvement by physiotherapists in providing advice to patients about 
medicine, and substantial involvement in administering both prescription only and non-
prescription medicines in countries where research was identified. Key areas in which 
physiotherapists administer medicines indicate where a prescribing role is likely to be 
beneficial: musculoskeletal conditions, respiratory conditions and sports injury. The main drug 
types administered are bronchodilators, NSAIDs and analgesics. Involvement in MMA varied 
according to setting and context and while there was general support for an increased MMA 
role, this varied in and across geographical regions and settings. Greater need for MMA was 
reported amongst private practitioners (34,37), first contact practitioners  and by those working 
in rural settings with poor access from other sources (37). Indeed, the geographical spread of 
studies suggests that interest predominates in countries with larger rural populations, or 
stretched healthcare resources, where extended medicines roles could improve efficiency or 
meet gaps in existing provision, as is often the case with nurse prescribing (4).  
Findings indicate a need to improve knowledge and understanding of medications that are 
commonly recommended or administered, such as NSAIDs. While evidence from the client 
perspective is limited (44), a high patient demand for information about medicine was reported, 
however levels of training and legislation to support safe MMA were inconsistent with this 
demand (33-34). Development of jurisdictional support for nurse involvement in MMA is 
similarly reported to vary internationally (3), but research indicates that where appropriate 
support and training are in place there is scope for improving patient care (4), as may also be 
the case for AHPs (51). Findings suggest that a more strategic approach to setting educational 
standards and competencies at national level is required. Legislation in the UK determines 
which professions may act as prescribers, and prescribing competencies (52) and educational 
requirements are set out in prescribing standards, which for AHPs are overseen by the Health 
and Care Professions Council (53). Work has also taken place to provide a national definition 
and framework for multi-professional advanced clinical practice roles in order to promote 
consistency in the development of these roles in England (54). However, there is an argument 
that preparation for medicines management should begin at pre-registration level and, with this 
in mind, consultations are underway to overhaul standards for the delivery of nursing and 
midwifery education in the UK to ensure that nurses are prepared to undertake more complex 
tasks required of them in the modern health service (55). Similar work on defining and 
regulating prescribing models for AHPs is underway in Australia (56). 
Research on prescribing was restricted to views about a potential prescribing role, perhaps 
reflecting the early stage in the development of these prescribing roles internationally. Barriers 
relating to liability, adequate training and role conflict echo those reported in the early days of 
nurse prescribing (57), as do anticipated benefits (3,6). Other countries are considering the 
introduction of extended medicines management roles for AHPs (56) and prescribing 
responsibilities are being extended to other AHPs in the UK, including dieticians and 
radiographers (58). In order to understand the contribution that AHPs can play in the UK and 
elsewhere in leading improvements to service provision and expanding reach to remote areas, 
an urgent and more robust approach to evaluation of ESP is required. 
Limitations of this review are that the exclusion of low quality studies may have restricted the 
diversity and range of descriptive findings relating to medicines management activity globally. 
There was inconsistency in the use of terms, indicating that the legal distinction between 
‘prescribing’ and ‘administering’ medicine is not widely agreed and differs between countries. 
 
CONCLUSION 
Extending the scope of allied health care practice to include more medicines management has 
the potential to improve patient care and contribute to building efficient and sustainable health 
systems. This review identified a mismatch in many countries between client demand for 
medicines and medicine advice and the educational preparation and governance to support 
physiotherapists to meet this demand. In the UK where such legislation is in place, research is 
required to evaluate the impact of prescribing and other medicines management activity by 
physiotherapists and podiatrists and to explore the views of key stakeholders (including 
patients, doctors, nurses, pharmacists, commissioners) regarding policy change in relation to 
this. The review indicates a need to improve physiotherapy education at under-graduate and 
post-graduate level regarding the use of commonly used medications such as NSAIDs, 
including education on clinical indications, contraindications, drug interactions and side 
effects. Working towards agreed standards of practice for different models of medicines 
management, the associated competencies and educational requirements, may help to clarify 
and improve consistency of practice for AHPs. A review of legislative and educational support 
for physiotherapist involvement in delivering medicines to patients is recommended in 
countries where this practice is common.  
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Table 1. Glossary of terms 
 
Administration 
 
To give a medicine either by introduction into the body, whether by direct 
contact with the body or not (e.g. orally or by injection), or by external 
application, e.g. application of an impregnated dressing (6). 
Advice The act of giving information, opinion, or recommendation for further 
intervention or actions to service users pertaining to aspects of the condition for 
which they are seeking intervention (16). This may include guidance to seek the 
opinion of another health professional. To advise on the use of medicines, it is 
imperative that the professional has the appropriate knowledge of the medicine, 
its pharmacology and dynamics and how it is handled in the body, as well as the 
legal framework surrounding medicines.  
Exemptions ͚ProfessioŶ speĐifiĐ eǆeŵptioŶs ;estaďlished ǀia StatutorǇ IŶstruŵeŶtͿ alloǁ 
certain listed medicines to be sold/supplied and/or administered to patients by 
podiatrists who have attained the required qualifications and are recognised by 
the Health and Care Professions Council as competent to do so (as indicated by 
specific annotations to the HCPC register). Exemptions are not a form of 
presĐriďiŶg.͛;ϭϭͿ. 
Extended scope of 
practice 
Practitioners, such as extended scope physiotherapists, working at a high level of 
expertise who have extended their practice and skills in a specialised clinical area 
(17). 
Independent 
prescribing (IP) 
Prescribing by an appropriate practitioner responsible and accountable for the 
assessment of patients with undiagnosed or diagnosed conditions and for 
decisions about the clinical management required, including prescribing (18). 
Injection Therapy The delivery of POMs and other products by injection to intra and extra-articular 
tissues and joint spaces (19) with the objective of reducing inflammation and 
improving joint mobility. Considered a post-registration technique in 
physiotherapy (20). 
Medicines 
Management Activities 
(MMA) 
 
A system of processes and behaviours that determines how medicines are used 
by patients and by the NHS (21). For the purposes of this review, MMA refers to 
prescribing and/or the process of giving advice about medicines and the supply 
and administration of medicines. 
Non-medical 
Prescribing (NMP) 
Prescribing by specially trained nurses, optometrists, pharmacists, 
physiotherapists, podiatrists and radiographers, working within their clinical 
competence as either independent or supplementary prescribers (18). 
Patient Group 
Directions (PGD) 
Written instructions that allow the supply and/or administration of a specified 
medicine(s), by named, authorised, registered health professionals, to a pre-
defined group of patients needing prophylaxis or treatment for a condition 
described in the PGD, without the need for a prescription or an instruction from 
a prescriber (22). 
While PGDs are designed for POM, some organisations use PGDs as best practice 
for over the counter (OTC) medicine. 
Patient Specific 
Directions (PSD) 
Written instructions by an independent prescriber for medicines to be supplied 
and/or administered to a named patient after the independent prescriber has 
assessed the patient on an individual basis (11). PSDs provide a clear 
demarcation of responsibilities with the independent prescriber responsible for 
prescribing, and a delegated individual or profession responsible for the supply 
and/or administration of medicines 
Prescribing To authorise in writing the supply and administration of a medicine or other 
healthcare treatment for a named individual patient (22). 
Supplementary 
Prescribing (SP) 
The ǁorkiŶg defiŶitioŶ of suppleŵeŶtarǇ presĐriďiŶg is “a ǀoluŶtarǇ partŶership 
between an independent prescriber (a doctor or dentist) and a supplementary 
prescriber to implement an agreed patient-specific Clinical Management Plan 
ǁith the patieŶt͛s agreeŵeŶt ;ϮϯͿ. 
Supply To provide a medicine directly to a patient or carer for administration (6). 
n.b. the definitions and terms used in this table may be specific to the UK context 
 
Table 2. PICO 
 
Population Defined as the care provided by podiatrists or physiotherapists across a range of 
roles; and across all patient groups in all care settings. This may also include the 
range of patients under the care of these professional groups. 
 
Intervention If applicable, any intervention by podiatrists or physiotherapists relating to the 
use of prescribing (defined as authorising in writing the supply and/or 
administration of a medicine or other healthcare treatment for a named 
individual patient) and/or medicines management activity (involving giving 
advice about medicines, or the supply and administration of medicines to 
patients or carers). Types of interventions will include whether they impact on 
workforce issues or patient/ carer issues. 
 
Comparator The use of prescribing staff and services that support this role compared to non-
prescribers within services; or no comparator for descriptive studies. 
 
Outcome Any patient-reported, service or health related outcomes that are measured or 
identified across services areas. 
 
 
  
Table 3  Data Extraction Form 
First 
author, 
year, 
(country) 
Method Sample/ Number of 
Participants/ Response 
rate 
Content of 
Intervention/Medicines 
Management or 
Prescribing Activity  
Main outcome 
measures 
Methods used to 
support reliability and 
validity 
Main Findings MMAT score 
Atkins, 
2003 
(UK) 
Phenomenologi
cal study 
unstructured 
interviews  
n=11 
 
Convenience sample, 
MSK PTs (3 ESPs), from 
primary/ secondary care 
(n=5), private practice 
(n=5), commercial 
industry (n=1). 
 
Barriers and facilitators 
to implementation of 
injection therapy 
Not applicable Transcriptions verified 
by participants. 
 
 Facilitators: physician support, good 
relationship and communication 
with GPs; use of PGDs  Barriers: physicians, manager & PT 
resistance; quality of supervision 
during training; organizational 
barriers in setting up PGDs; lack of 
prescriptive authority   Level of responsibility and potential for 
adverse reactions linked with 
anxiety  
75% 
 
Ball, 2007 
(UK) 
Retrospective 
case note 
review 
n=643 patients attending 
ED March-May 2005 with 
closed musculoskeletal 
conditions 
 
 
 
Comparison of 
management of closed 
musculoskeletal 
conditions by ESP 
(n=164)/ENP (n=142) 
/doctors (SHO n=130) 
/registrar (n=135)/ 
consultant (n=72)  
Frequency of  
x-rays, patients 
given advice, 
analgesics, 
bandages or 
support, & follow-
up  
 
Not discussed  ESPs documented more general advice 
than other clinicians (p=0.07)  ESPs most likely to record giving of 
advice re analgesia (p=0.001).   ESP most likely to suggest follow up 
(p=0.03) 
 
 
75% 
 
Birchall, 
2008 
(UK) 
Prospective, 
consecutive 
case series with 
follow up 
 
n=98/ 100 recruited 
patients with 
osteoarthritis in one or 
both knees referred to PT 
led clinic, by Hospital 
consultant (n=56 
completed study to 52 
weeks) 
 
 
 
Patterns of clinical 
change using repeated 
measures based on 
course of 5 x weekly 
intra-articular knee 
injections (hyaluronic 
acid) administered by 
ESP, with relative rest 
for 48 hrs & avoidance 
of strenuous activity & 
gradual return to 
normal activities.  
 
 
Primary: pain, 
physical 
functioning and 
patient global 
assessment of 
change @ 0, 5, 
13, 26 and 52 
weeks.  
 
Secondary: oral 
and topical 
analgesia,  BMI 
Western Ontario 
McMaster Universities 
Osteoarthritis Index 
(WOMAC) Likert 3.0 
pain (0–20) and 
physical function (0–68) 
 
Outcome Measures in 
Rheumatology and 
Osteoarthritis Research 
Society International 
OMERACT-OARSI) used 
to classify outcome at 
each follow-up  
 Significant pain reduction at five 
weeks, still below baseline at 13 
weeks   Variability in response, and return to 
baseline levels similar to previous 
RCTs in this area  Physiotherapy led knee injection 
service achieved high treatment 
compliance rates and comparable 
functional outcomes to those 
reported in similar RCTs with Doctor 
led-service 
 
 
100% 
 
Braund, 
2011 
(New 
Zealand) 
Questionnaire n=278/ 948 (29.3%) MSK 
PTs contacted via New 
Zealand Society of 
Physiotherapists 
 
Exploration of current 
practices regarding 
recommendation of 
paracetamol and 
NSAIDs to patients; 
knowledge with regards 
to adverse effects of 
these classes of 
medications and 
patient factors 
associated with 
increased risk of 
adverse effects. 
N/A Previous survey 
(Braund 2006) Pilot testing 
 
 
  > 70% sometimes or often 
recommended oral NSAIDS or oral 
paracetamol  More likely to recommend 
paracetamol bought direct from 
supermarket or pharmacy (53%) and 
to consult a pharmacist or GP about 
NSAIDs (44%).   83% provide information on side 
effects, 69% on potential risks, 
55.5% recommend dose: i.e. 
practicing outside general scope of 
physio practice   Variable knowledge re potential side 
effects and risks – 70% identified 
gastrointestinal upset/bleed, < 31% 
risks related to respiratory, renal or 
allergies  PTs who regularly recommended 
identified significantly more risks  
(p=0.004) 
50% 
 
Daker-
White, 
1999 
(UK) 
Randomized 
controlled trial 
n=481 patients (244-
Doctor care, 237 PT care) 
new GP referrals to two 
secondary care 
orthopedic outpatients.  
 
Allocation sequence 
generated by random 
numbers. 
 
(Doctor care: 191/244 
(78%) , PT 192/237 (91%) 
completed study) 
Assessment and 
management of newly 
referred patients by 
extended scope 
physiotherapists or 
doctors 
 
Physiotherapists 
received 1:1 training 
with consultant and 
could instigate (but not 
prescribe) the same 
management options as 
doctors, including intra-
articular injections, oral 
NSAIDs and analgesics. 
 
 
Primary:  
pain, functional 
disability and 
perceived 
handicap at 4/12 
follow up  
 
 
 
 
 
 
 
 
 
 
 
Secondary:  
Disease Repercussions 
Profile, Functional disability: 
Oswestry, back pain 
questionnaire WOMAC 
questionnaire, St 
MiĐhael͛s Hospital PatieŶt 
Self Evaluation, Modified 
American Shoulder & 
Elbow Surgeons Shoulder 
Patient Self-Evaluation 
Form Vvisual analogue  
scales 
 
 
 
 
Self-efficacy 
questionnaire, Hospital 
No clinically important differences 
between the two groups in primary 
outcome (>0.05) PTs higher level of Satisfaction on the  
͚peƌĐeiǀed tƌeatŵeŶt ƋualitǇ͛ ;p=Ϭ.ϬϬϭͿ  PTs administered equal numbers of  
intra-articular injections compared to 
doctors (p=0.70), fewer intra-muscular 
injections (7 vs. 1, p=0.04) and no NSAIDs 
or analgesics (p=0.06).   PT in-hospital costs were less due to  
less x-ray requests ( p<0.001) & surgical 
referrals (p=0.005).  
 
75% 
 
Health & 
psychological 
status, health 
related 
quality of life, self 
efficacy, 
satisfaction with 
care & GP, 
resource use 
 
a mean 5.6 
months follow-up 
 
 
Anxiety and Depression 
Scale (psychological 
status), SF-36 (general 
health status 
measure), EuroQol EQ-
5D, process data 
 
 
 
Donato, 
2004 (USA) 
Questionnaire 
 
 
n=222/ 462 (49%) PTs 
 
Of which PCC PTs= 212 ( 
n-56.1% were primary 
contact military PTs & 
43.9% were primary 
contact civilian PTs) who 
were compared to  
non-primary contact 
civilian PTs (n=103/250). 
 
Exploration of 
frequency & perceived 
importance of 
professional 
responsibilities, 
procedures (i.e. tests, 
measurements & 
interventions), and 
knowledge areas of PTs 
practicing in primary 
contact setting with PTs 
in non PCC settings. 
 
 
Not applicable  Content informed by  
literature review and 
panel of experts (n-19), 
and 3 round Delphi 
technique  Piloted 
 
 Only PC military MSK PTS have 
prescribing authority in US  OTC medicines were administered 
mainly for MSK by 61% (n=50) of 
military PTs, 38% (n=14) of civilian 
PTs conditions, and 6.2% (n=6) of 
non-primary contact PTs  Non-narcotic medications were 
administered by 49% (n=40) of 
military PTs and 16% (n=6) of civilian 
PTs respectively.  Significant differences in professional 
responsibilities between primary 
and non-primary contact PTs 
p<0.001 
75% 
 
Grimmer, 
2002 
(Australia) 
Questionnaire n=285/750 (38%) random 
sample of registered PTs 
in South Australia, 
Tasmania and Australia 
Capital  
 
 
   
Exploration of 
knowledge, treatment 
behaviours and 
attitudes of  regarding 
the use of NSAIDs in 
clinical practice 
Not applicable  Content informed by  
30 semi-structured 
interviews with PTs face, content &  
construct, validity, 
processes outlined by 
Carmines & 
Zeller (1979); Hunt et al 
(1982). Piloted 
 
55% (n=157) of PTs regularly made 
direct recommendations to patients 
about use of NSAIDs   Most popular recommendations were 
for use of OTC topical NSAIDS (83%), 
followed by oral NSAIDS (78%), 
often recommended by brand name 
(61%).  96% gave advice on precautions,> 80% 
contraindications & side effects and 
<45% dosage. 
50% 
 
  64% (n=182) directed patients to their 
physicians or pharmacists re NSAID 
purchase.    Only 26% gave advice on drug 
interactions  65% recorded discussions with 
patients regarding    Nearly 90% correctly identified side 
effects, contraindications and 
clinical application of oral NSAIDs.  > 40 % had poor knowledge of 
medicines legislation   Private PT strong support for 
prescribing legislations, but variable 
in other settings 
Holdsworth
2008 
(UK) 
Questionnaire 
 
117/ 161 (73% response 
rate) of PTS (n=47/64) 
and GPs (n=70/97) from 
26 general practices in 
Scotland engaged in pilot 
physiotherapy self-
referral scheme 
Exploration of the views 
of PTs and GPs on self-
referral and 
physiotherapy scope of 
practice, attitudes to 
prescribing and 
monitoring NSAIDs 
Not applicable  Content informed 
by clinician 
interviews  Piloted 
  
 70% (n=68) of GPs and 77% of PTs 
endorsed PTs practising as primary 
contact practitioners  > 80% PTs and GPs supportive of PTs 
monitoring & prescribing NSAIDs    38% GPs (n=26) thought prescribing 
should not be considered, only 10% 
(n=7) believed it would bring 
definite patient benefit.   
50% 
 
Kumar 
(2005) 
(Australia) 
Semi-structured 
interveiws 
n=30 PTs from South 
Australia, Tasmania and 
Australia Capital 
Territory,  Australia 
 
Views on understanding 
of the role of PTs in the 
use, recommendation 
& delivery of NSAIDS. 
 
Not applicable Transcripts verified by 
participants  (n=3) 
 High demand from patients for 
medicines information.   PTs regularly asked for advice on 
NSAIDs  Concerns about PT lack of knowledge 
of pharmacology to support advice 
given to patients, especially long 
term use of NSAIDs  Concern about poor access to patient 
medical records  Rural, sports and first contact PTs in 
support of PT prescribing of NSAIDs 
with pharmacist support  Hospital based PTs resistant to PT 
prescribing.  
 
50% 
 
Lansbury, 
1998 
(Australia) 
 
Questionnaire  n=472/600 (72.5%). 
Random sample of 25% 
registered physical 
therapists in New South 
Wales, Australia (n=2662) 
 
 
 
 
PT views on 
administration,  advice 
on POMs 
N/A  Content developed 
in consultation 
with the NSWPRB 
  Piloted-multiple 
stages 
 51.8%, (n=243) worked in private 
practice  Musculoskeletal (55.9%, n=261), sports 
(36.8%, n=172) and rehabilitation 
(23.3%, n=104) predominant 
specialities.  27.4 % (n=127) of PTs administered 
POMs; 40 % (n =48) on a daily or 
weekly basis. Frequency varied from 
daily (13%) to < monthly (49.2%) 
and the majority were administering 
the dose prescribed by a physician   Only 41 % (n=248) formally trained in 
administration of POMs.   Private practitioners more likely to give 
POMs (p<0.0001).  Common drugs administered: 
bronchodilators 84.6% (n = 110) 
topical agents 29.2 % (n·= 38), 
analgesics, 16.2 % (n =21), NSAIDs 
6.9% (n = 9) and antibiotics (6.2%). 
 
50% 
 
Lansbury, 
2002a 
(Australia) 
Reporting 
from 
Lansbury 
1998 
dataset 
 
Questionnaire  n=472/600 (72.5%). 
Random sample of 25% 
registered physical 
therapists in New South 
Wales, Australia (n=2662) 
 
 
PT experience and 
views on providing 
advice on POMs. 
 
N/A  Content developed 
in consultation 
with the NSWPRB  Piloted-multiple 
stages 
 85.9% (n = 399) gave POM advice as 
patients requested it (77.9%, n=311) 
or incorrect usage detected (74.9%, 
n=178)   Advice given included 73.8% (n=299) 
how to take medicines, 53.1% 
(n=215) when to take & 26.9% 
(n=109) frequency  14.2% (n=66) did not give advice as 
considered themselves not 
responsible, untrained, or not 
legally entitled to do so.  74.4% (n=343) made 
recommendations for new drugs, 
although this was accompanied by 
advice to consult a doctor in 94% 
(n=330) of cases. 
50% 
 
 Medicines recommended included 
analgesics, NSAIDs, general anti-
inflammatory medicines and 
inhalers.   The amount of advice given was 
associated with years of experience 
(p<0.05) and working in private 
practice (p<0.05) 
 
Lansbury, 
2002b 
(Australia) 
 
Reporting 
from 
Lansbury 
1998 
dataset 
 
Questionnaire n=472/600 (72.5%). 
Random sample of 25% 
registered physical 
therapists in New South 
Wales, Australia (n=2662) 
 
PTs views and practice 
in administration or 
providing advice on 
over the counter (OTC) 
medicines. 
N/A  Content developed 
in consultation 
with the NSWPRB  Piloted-multiple 
stages 
 OTC MMAs variable, 82% (n=358)  
gave advice at some point,    Providing information on dose 
schedule, safety & to see 
pharmacist/GP was common.   33% (n=147) administered non- 
prescription medicines, often 
independent of physician guidance.  Greater pharmacology training 
required; 10.3% (n=35) PTs aware of 
contraindications or side effects 
with 18.5% (n=80) reporting 
inadequate pharmacology training. 
 
50% 
 
McClellan, 
2006 
(UK) 
Prospective 
cohort study 
Patient satisfaction 
n=351/780 (45%) 
response rate 
 
Functional outcome of 
unilateral ankle soft 
tissue injury n=91/489 @ 
4 weeks   
 
 
Evaluating the effect of 
introducing an ESP in 
the adult ED, comparing 
three different 
practitioners: doctors, 
emergency nurse 
practitioners (ENPs), 
and ESPs. 
 
 
Primary: Patient 
satisfaction 1 
week after ED 
attendance. 
Secondary: 
Functional 
outcome of 
unilateral ankle 
STI at 4 and 16 
weeks after 
injury, pain VAS. 
Validated SF- 36, 
piloting of satisfaction 
questionnaire, 
Visual analogue scores 
 
 ESP > patient satisfaction than for 
ENPs or doctors for good 
advice/information (p=0.03), time to 
ask questions (p=0.05), and 
explanation of assessment (p=0.01).  ESP>overall satisfaction was higher 
compared to ENP and doctors 
(p=0.048).  ESP< waiting time & longer 
consultations than  doctors or ENPs   Functional outcome scores were 
comparable across groups. Trend to 
improved pain and function one 
month after injury in patients seen by 
ESPs compared to doctors and ENPs 
 
 
50% 
 
 McClellan, 
2012 
(UK) 
Randomised 
controlled trial. 
Adult patients with 
peripheral soft tissue 
injury <72 hour old were 
block randomised to 
receive care from an ESP 
(n=126), ENP (n=123) or 
any grade ED doctor 
(n=123) (total n=372). 
To evaluate the clinical 
effectiveness of soft 
tissue injury 
management by ENPs, 
& ESPs compared 
routine ED Doctor care. 
Primary outcome: 
Functional 
recovery @ 2 & 8 
weeks 
 
Secondary: Health 
related Quality of 
Life preference 
based utility 
scores, clinician 
contact time, 
frequency of 
treatment types, 
medicines used, 
health resource 
use. 
Disability of the Arm, 
Shoulder and Hand 
score (DASH) for upper-
extremity injuries,&  
Lower Extremity 
Functional Score (LEFS) 
for lower-extremity 
injuries 
 
Validated SF-12v2 and 
SF-6D,  
 
 
 ESPs achieved equivalent clinical 
outcomes to routine models of care 
delivered by ENPs and doctors  Results showed equivalence in 
functional outcomes and Quality of 
Life with those treated by doctors at 
8 weeks and no difference in 
recovery rates between the 3 
professional groups.  ESPs administered fewer analgesics 
and anti-inflammatories (p<0.001) 
and had longer consultation times 
 
 
75% 
 
McClellan, 
2013 
(UK) 
 
Analysis of 
McClellan 
2012 
dataset 
Randomised 
controlled trial. 
Adult patients with 
peripheral soft tissue 
injury <72 hour old were 
block randomised to 
receive care from an ESP 
(n=126), ENP (n=123) or 
any grade ED doctor 
(n=123) (total n=372). 
To evaluate & compare 
cost effectiveness of 
treatment of soft tissue 
injury by ENPs, & ESPs 
and ED Doctor care  
 
 
 
 
Primary 
outcomes: cost 
per hour/ patient 
contact and cost 
per patient per 
hour.   
                                                        
Secondary 
outcomes: direct 
cost per hour per 
patient & indirect 
cost per hour per 
patient contact 
 
based on data 
collected during 8 
weeks following 
injury 
  Direct costs  for ESP  are at best 
equivalent, if not more expensive 
than routine care  Indirect costs for ESPs were equivalent 
or cheaper to routine care,  mainly 
due to preference for supplying 
supportive equipment (e.g. leg 
crutches, braces) than administering 
medicine 
75% 
 
Morris 
2015 
 
(Australia) 
Prospective 
observational 
cohort study 
with embedded 
N=51,223 episodes of 
care treated in 
Emergency Department 
(ED), of which 13,495 
ǁeƌe tƌeated iŶ ͚Fast 
To assess the impact of 
Advanced Scope of 
Practice Physiotherapist 
(ASoP-PT) service on 
Primary 
Length of stay 
Length of wait 
 
Secondary 
  836 (6.19%) of the 13,495 episodes 
attending Fast Track were treated 
by the ASoP-PT. Patients were 
predominantly classed as semi-
75% 
qualitative 
interview study 
TƌaĐk͛ seƌǀiĐe oǀeƌ 53 
week period (Oct 2011-
Nov 2012).  
Consecutive patients. 
Fast Track designated as 
less urgent, minor 
illnesses and injuries, 
predominantly MSK 
 
Patient interviews (n=11) 
Physician and nurse 
interviews (n= not stated) 
triage targets, patient 
and staff satisfaction 
 
ASoP-PT was a qualified 
prescriber but unable 
to prescribe or 
independently provide 
medicines management 
under local legislation 
and so these tasks were 
undertaken by a 
physician. 
 
Patient and 
service activity 
data 
Staff and patient 
satisfaction 
urgent (68.3%) and non-urgent 
24.5%).  Length of stay and length of wait were 
significantly reduced on shifts where 
the ASoP-PT was present. There was 
no significant difference in 
compliance with triage targets.   Requests for imaging and prescriptions 
constituted between 50-70% of the 
volume of provision per patient per 
month. Xray imaging was ordered 
most frequently (72.8%, n=577).  
Panadine Forte (20.8%, n= 165) and 
paracetamol (17.3%, n= 137) the 
most frequently ordered 
medications.  No adverse events were reported  Doctors and nurses positive views 
about ASoP-PT impact on service 
efficiency and increased knowledge. 
Majority of patients were satisfied 
with ASoP-OT care, although not 
always aware that they were seeing 
a physiotherapist 
 
Onigbinde, 
2012 
(SW 
Nigeria) 
Questionnaire n=152/ 200 (76% 
response rate of which 
135 analysed) 
 
Questionnaire hand 
delivered to PTs from 5 
university teaching 
hospitals, 2 state, 1 
private, 2 private clinics, 
and 3 PT training schools. 
 
Exploration of 
knowledge of topical 
medicines in clinical 
practice. 
. 
 
 
NA Four section 
questionnaire adapted 
from Grimmer et al 
(2002).  
 
Piloted 
 
 41% (n=55) had recently updated their 
knowledge on topical medicines, 
whilst 17.8% (n=24) had never 
updated  Knowledge of topical medicines 
pharmacology poor; mean score 
5.21 (SD 2.52) out of 16  Knowledge of indications, actions and 
side effects of common topical 
agents poor: 81% (n=109) 
misunderstood the mechanism of 
action for topical NSAIDs and 66% 
(n=89) were unable to identify risks 
associated with topical medicines. 
50% 
 
 Significant association between length 
of clinical experience and 
pharmacology knowledge (p=0.03)  Limited access to physiotherapy 
training opportunities in 
pharmacology identified 
 
Onigbinde, 
2013 
(SW 
Nigeria) 
 
 
 
 
 
 
Questionnaire n=107/150 (71.3%) PTs  >  
1 year qualified 
experience from 
government and private 
hospitals; clinics and 
training institutions. 
Exploration of 
knowledge of topical 
medicines in clinical 
practice 
 
Views on pharmacology 
education on topical 
medications 
 
NA Four section 
questionnaire adapted 
from Grimmer et al 
(2002) & Onigbinde, 
2012 
  
 
Piloted 
 
 Respondents had good knowledge of 
indications of topical analgesics e.g. 
Diclofenac   78% (n=83) were unable to correctly 
identify the FTU gram equivalent for 
topical cream and gel  55.1% (n=59) of respondents had 
received undergraduate 
pharmacology education  Level of knowledge not associated 
undergraduate pharmacology 
training  65.4% (n=70) supported legislation 
granting authority to prescribe 
topical medicines  
50% 
 
Richardson 
2005 
(UK) 
 
 
 
Randomised 
Controlled Trial 
766/844 (91%) eligible 
consented &randomised 
 
Block randomisation in 
A&E department patients 
with soft tissue injury 
without fracture 
 
a) Initial assessment and 
management by a 
physiotherapist (n=382): 
return to usual activity 
n=278 (73%), Satisfaction 
n=306 (80%), 3 months 
n=207 (54%), 6 months 
n=198, (51%) 
 
 
Comparison of clinical 
effectiveness and costs 
of two alternative 
assessment routes for 
patients presenting 
with musculoskeletal 
problems to an A&E 
department. 
 
Two physiotherapists 
(III grade) worked A&E 
day shifts for the 
purpose of the project 
and were able to 
request radiographs 
and prescriptions for 
analgesia from medical 
staff. 
Primary outcome: 
days before 
return to usual 
activity 
 
Secondary 
outcome: patient 
satisfaction, 
quality of life, 
function and pain 
levels at 3 and 6 
months  
 
Economic data 
collected on use 
of health and 
social services 
and personal 
Pilot study 
Goldstein satisfaction 
instrument (2000) 
 higher satisfaction in physiotherapy 
arm (89% to 74%, p=0.0001)   higher quality of life at 3 months in 
physiotherapy arm, no differences 
at 6 months  Median days before return to usual 
activities (available for 73% of those 
randomised) was greater in the 
physiotherapist group (41 days 
compared with 28.5 days; hazard 
ratio 0.85 p=0.071). not significant  Patterns of service use were different, 
e.g. the physiotherapy arm saw 
fewer prescriptions issued but 
higher referrals to other services 
but. no significant differences in 
service related or health & social 
care costs 
50% 
 b) Routine A&E 
assessment and 
management by either a 
doctor or emergency 
nurse practitioner 
(n=384).  
 
Return to usual activity 
n=280 (73%), Satisfaction 
n=303 (79%), 3 months 
n=209 (54%), 6 months 
n=179 (47%) 
 
costs at 
treatment and 
follow-up 
 
 
Sullivan, 
1999 
(Australia) 
 
Reporting 
from 
Lansbury 
1998 
dataset 
 
 
Questionnaire n=472/600 (72.5%). 
Random sample of 25% 
registered physical 
therapists in New South 
Wales, Australia (n=2662. 
Knowledge of 
prescription only 
medicines 
N/A Content developed in 
consultation with the 
NSWPRB. 
 
Piloted-multiple stages 
 Documentation of medicines history 
varied; 52.9% (n = 244) kept a record at 
every consultation  Only 28.1% (n = 125) felt adequately 
Trained in POMs most of the time: 12.3% 
(n = 57) never felt adequately trained   Knowledge of contraindications varied  
only 38.4%  (n = 179) aware most times  Private practice PTs reported greater 
knowledge of the effectiveness of POMs 
than PTs in public health settings (< 0.05)  
 
50% 
 
Unger 2006 
(South 
Africa) 
 
 
Questionnaire n=448/4480 (10%) 
registered  PTs 
 
Views on medicines 
administration and 
prescribing. 
N/A 3 sections adapted 
from Grimmer (2002)  
 
Piloted 
 
 The inclusion of pharmacological 
training within undergraduate 
qualification was reported by 53% of 
PTs  60% had never updated this 
knowledge through formal or 
informal education, although 90% 
had sourced drug information in the 
past 6 months   64% (n=294) of PTs administered 
medicines including inhalers and 
NSAIDs  45% (n=132) of those administering 
medicines considered 
contraindications  
50% 
 
 26% (n=119) supplied respiratory 
medicines, contrary to medicines 
legislation  70% of PTs surveyed and 63% 
supported a prescribing role  Acceptance of a prescribing role was 
dependent upon this remaining a 
voluntary option guided by clearly 
defined guidelines and scope of 
practice 
 
  
 Appendix 1. List of databases and sources searched 
 
 
Databases Professional organisation websites 
 
Trial Registers 
MEDLINE The Chartered Society of Physiotherapy (UK) -
http://www.csp.org.uk/ 
ClinicalTrials.gov -  
https://clinicaltrials.gov/ 
CINAHL The American Physical Therapy Association - 
http://www.apta.org/ 
International Standard Randomised 
Controlled Trials -
http://www.isrctn.com/ 
Cochrane Central 
Register of 
Controlled Trials 
 
The Australian Physiotherapy Association -
http://www.physiotherapy.asn.au/ 
Australian New Zealand Clinical Trials 
Registry - http://www.anzctr.org.au/ 
OpenGrey - 
http://www.open
grey.eu/ 
 
The New Zealand Physiotherapy Association - 
http://physiotherapy.org.nz/ 
UK Clinical Research Network Study 
Portfolio -
http://public.ukcrn.org.uk/search/ 
Frontline 
 
The Canadian Physiotherapy Association - 
http://www.physiotherapy.ca/ 
 
Google Scholar 
 
The Nigerian Society of Physiotherapy - 
http://www.nigeriaphysio.org/ 
 
 The South African Society of Physiotherapy - 
http://www.physiosa.org.za/ 
 
 The Society of Chiropodists and Podiatrists –  
http://www.scpod.org/# 
 
 The British Chiropody and Podiatry Association –  
http://www.bcha-uk.org/ 
 
 The Podiatry Board of Australia -
http://www.podiatryboard.gov.au/ 
 
 The Podiatrists Board of New Zealand - 
http://www.podiatristsboard.org.nz/default.asp
x 
 
 
 
Appendix 2. Extract of search string 
 
 
 
 
Database: Medline  
Platform: EBSCO 
Limits:   
Physiotherapy Limiters - Date of Publication: 19850501-20140731, Human only 
Podiatry Limiters - Date of Publication: 19680101-20160531, Human only 
Search modes - Boolean/Phrase 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30  
͞physical therap*".ti.ab 
͞phǇsiotheƌap*͟.ti.ab 
 (MH "Physical Therapy Modalities") 
͞eǆteŶded scope of pƌaĐtiĐe͟.ti.aď 
͞ESP".ti.ab 
͞eǆteŶded scope physiotherap*͟.ti.aď 
͞enhanced scope of practice͟.ti.aď 
͞adǀaŶĐed pƌaĐtiĐe*͟ti.ab 
͞adǀaŶĐed pƌaĐtitioŶeƌ*͟ti.ab 
͞allied health pƌofessioŶal*͟.ti.ab 
prescrib*.ti.ab 
͞pƌesĐƌiďiŶg ƌight*͟.ti.ab 
͞ŶoŶ-medical pƌesĐƌiď*͟.ti.aď 
͞iŶdepeŶdeŶt pƌesĐƌiď*͟ .ti.ab 
͞suppleŵeŶtaƌǇ pƌesĐƌiď*͟.ti.aď 
͞patient group diƌeĐt*͟. ti.ab 
͞patient specific diƌeĐt*͟. ti.ab 
exemption*ti.ab 
͞iŶjeĐtioŶ theƌap*͟ ti.ab 
Podiatry.ti.ab 
(MH "Podiatry") 
 ͞speĐialist podiatƌist͟.kw 
͞CoŶsultaŶt Podiatric “uƌgeoŶ͟.kw 
͞podiatƌiĐ suƌgeoŶ͟.ti.ab 
OR/1-10         (Physiotherapy terms  ) 
OR/8-10 OR/20-24 (Podiatry terms  ) 
OR/11-19                    (Prescribing terms) 
25 AND 27 
26 AND 27 
28 OR 29 (Physio and Pod together) 
 
Key  
Ti– title word 
Ab – abstract word 
MH – Main index/ MeSH term 
Kw – Key Word 
 
 
Appendix 3. PRISMA flow chart 
 
 
 
 
 
 
 
 
Records identified through 
database searching  
(n =1243) 
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Additional records identified through other sources  
(n=73)  
 32 articles hand search  41 articles professional websites 
 
Records after duplicates removed (n=130)  
n =1186 
Titles screened  
n =1186 
Records excluded  
n =1052 
n=1008 not relating to prescribing/MMA 
n=44 prescribing/MMA not performed by 
Full-text articles assessed 
for eligibility  
n=123 
Records excluded  
n =11 
n=11 prescribing/MMA not performed 
Empirical studies included 
in review 
(n =21) 
Abstracts screened  
n =134 
Eligible articles n=32  
 
 
Records excluded  
n =91 
 
n=69 non-empirical (reviews or 
protocols)  
n=17 interventions not performed by PP 
n=3 full text unavailable 
Records excluded  
n =11 
n=11 empirical studies < 50 MMAT 
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